A disease with no treatment options, until Wednesday

Families living with Alexander disease have never had an approved treatment to offer their doctors a real option beyond managing symptoms as the condition progressed. That changed Wednesday, when the FDA approved Zanvastro, known generically as zilganersen, as the first-ever treatment for the disease, and the first therapy of any kind designed to directly target the protein buildup that actually causes it. Emily Freilich, director of the Division of Neurology I at the FDA's Center for Drug Evaluation and Research, put the significance in stark terms: "For patients with Alexander disease and their families, there have been no approved treatment options, only supportive care while the disease progresses."

Alexander disease is genuinely rare, estimated to affect roughly 300 people in the United States, a scale so small that most neurologists will never encounter a single case in their careers. That rarity is precisely why a dedicated approved treatment took this long to arrive, and why Wednesday's decision carries outsized weight for the small community of patients and families who've had nowhere else to turn.

What actually goes wrong in this disease

Alexander disease is a progressive, often fatal neurological disorder caused by mutations in the gene responsible for producing glial fibrillary acidic protein, or GFAP, a structural protein found in astrocytes, the star-shaped support cells that maintain healthy brain function. In Alexander disease, the mutated gene causes GFAP to accumulate abnormally inside these cells, progressively damaging the nervous system and producing a wide range of symptoms including seizures, loss of developmental milestones, difficulty walking, muscle weakness, and dangerously increased pressure inside the brain. The disease can affect people across an unusually broad age range, from infancy through adulthood, and its severity and progression pattern varies considerably depending on when symptoms first appear.

Because AxD stems from a buildup of a protein the body is producing in excess, rather than a protein deficiency, the therapeutic logic is fundamentally about turning down production before the abnormal protein has a chance to accumulate and cause further damage, a considerably more direct approach than symptom management alone can offer.

How the drug actually works

Zanvastro is an antisense oligonucleotide, a class of RNA-targeted medicine designed to bind to and degrade the messenger RNA that cells use as a blueprint to build a specific protein, in this case, the abnormal GFAP driving Alexander disease. By reducing how much of that pre-messenger RNA survives to actually get translated into protein, the drug lowers the amount of toxic GFAP accumulating in astrocytes before it can contribute to further neurological damage. It's the same broad drug class behind other high-profile rare disease therapies developed by Ionis Pharmaceuticals, the Carlsbad, California-based biotech behind Zanvastro, including Spinraza for spinal muscular atrophy.

The drug is administered as a 50 mg intrathecal injection, meaning it's delivered directly into the spinal canal by a trained healthcare professional, once every three months. That delivery method reflects a broader pattern in neurological antisense therapies: because the blood-brain barrier blocks most drugs from reaching the central nervous system in meaningful concentrations when given through a standard injection or pill, direct intrathecal delivery is often the only practical way to get an RNA-targeted therapy to the brain and spinal cord tissue where it's actually needed.

The trial data behind the approval

The FDA's decision rests on a multicenter, randomized, controlled clinical study enrolling 49 pediatric and adult patients with Alexander disease aged two years and older, alongside a separate open-label substudy covering four patients younger than two. Because the disease is so rare and its patient population spans such a wide age range, the FDA evaluated evidence supporting an indication covering the full spectrum from infancy through adulthood, a notable regulatory choice given how thin the available patient pool naturally is for any single narrow age bracket.

The core efficacy result centered on gait speed. In patients aged five and older who had measurable difficulty walking at baseline, those treated with zilganersen showed significantly better performance on the 10-Meter Walk Test at week 61 compared with untreated controls, with a least-squares mean difference of approximately 33.3%, a result that reached statistical significance. In a younger cohort aged two to four, treated children actually improved on a separate motor function measure, the GMFM-88 scale, while untreated controls in that age group declined over the same period, a 22.9-point gap that reached statistical significance as well and offers real support for the value of starting treatment earlier in the disease's course.

Why the FDA moved this quickly on so little data

A trial population of 49 patients is small by the standards most drug approvals require, but it's genuinely large relative to a disease affecting only around 300 people nationwide, meaning the study likely captured a meaningful fraction of the entire diagnosed U.S. patient population. The FDA granted zilganersen orphan drug, fast track, breakthrough therapy, and rare pediatric disease designations, along with a priority review voucher, the full suite of regulatory tools reserved for treatments addressing serious, otherwise-untreated conditions where waiting for a conventional, much larger trial simply isn't feasible given how few patients exist to enroll.

That regulatory pathway reflects a broader pattern in how the FDA handles ultra-rare diseases: when a condition affects too few people to support a traditional large-scale randomized trial, and patients currently have zero approved treatment options, the agency has shown increasing willingness to approve therapies based on smaller but methodologically sound studies, provided the effect size and biological rationale are compelling enough. It's a similar dynamic to how regulators recently cleared the first dedicated oral treatment for dermatomyositis, another rare disease where patients had previously relied entirely on therapies borrowed from other conditions rather than anything developed and tested specifically for their disease.

What this means for the roughly 300 patients it treats

Ionis has already established a support program called Ionis Every Step for patients starting on Zanvastro, offering disease education, assistance navigating insurance approval, and affordability program information, recognizing that a rare, complex disease requiring quarterly spinal injections creates genuine logistical and financial hurdles beyond simply having an approved drug exist. For a patient population this small, that kind of dedicated support infrastructure matters almost as much as the drug's approval itself, since navigating insurance coverage and specialty care access for an ultra-rare condition often proves nearly as difficult as the underlying disease.

Wednesday's approval doesn't cure Alexander disease, and the available trial data, while statistically meaningful, comes from a genuinely small patient population followed for just over a year. Longer-term data will be needed to fully understand how much the drug changes the disease's overall trajectory across a patient's full lifespan, particularly for the youngest patients who could potentially receive the therapy for decades. What Wednesday's decision does establish, immediately and unambiguously, is that families facing this specific diagnosis now have an actual treatment option pointed directly at the disease's underlying cause, something that simply did not exist the day before.